ABCL vs. NTLA
ABCL (AbCellera Biologics Inc.) and NTLA (Intellia Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, ABCL returned -23.34%/yr vs -29.38%/yr for NTLA. A 0.51 correlation means they provide meaningful diversification when combined.
Performance
ABCL vs. NTLA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ABCL achieves a 64.62% return, which is significantly lower than NTLA's 69.63% return.
ABCL
- 1D
- -1.92%
- 1M
- 8.27%
- YTD
- 64.62%
- 6M
- 52.57%
- 1Y
- 69.07%
- 3Y*
- -8.34%
- 5Y*
- -23.34%
- 10Y*
- —
NTLA
- 1D
- -3.17%
- 1M
- 21.03%
- YTD
- 69.63%
- 6M
- 61.89%
- 1Y
- 65.22%
- 3Y*
- -28.07%
- 5Y*
- -29.38%
- 10Y*
- -5.26%
ABCL vs. NTLA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
ABCL AbCellera Biologics Inc. | 64.62% | 16.72% | -48.69% | -43.63% | -29.16% | -64.46% | -34.03% |
NTLA Intellia Therapeutics, Inc. | 69.63% | -22.90% | -61.76% | -12.61% | -70.49% | 117.35% | -2.61% |
Correlation
The correlation between ABCL and NTLA is 0.54, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.54 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.59 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.54 |
Correlation (All Time) Calculated using the full available price history since Dec 11, 2020 | 0.51 |
The correlation between ABCL and NTLA has been stable across timeframes, ranging from 0.51 to 0.59 - a consistent structural relationship.
Fundamentals
ABCL:
$1.71B
NTLA:
$1.81B
ABCL:
-$0.48
NTLA:
-$3.58
ABCL:
21.31
NTLA:
25.43
ABCL:
1.82
NTLA:
2.91
ABCL:
$79.21M
NTLA:
$66.09M
ABCL:
$70.89M
NTLA:
-$33.92M
ABCL:
-$166.07M
NTLA:
-$299.32M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ABCL vs. NTLA — Risk / Return Rank
ABCL
NTLA
ABCL vs. NTLA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for AbCellera Biologics Inc. (ABCL) and Intellia Therapeutics, Inc. (NTLA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ABCL | NTLA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.23 | ||
| Sortino ratioReturn per unit of downside risk | +0.21 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.21 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 1.26 | 0.92 | +0.34 |
| Martin ratioReturn relative to average drawdown | 2.29 | 1.41 | +0.88 |
Loading charts...
Drawdowns
ABCL vs. NTLA - Drawdown Comparison
The maximum ABCL drawdown since its inception was -96.84%, roughly equal to the maximum NTLA drawdown of -96.45%. Use the drawdown chart below to compare losses from any high point for ABCL and NTLA.
Loading charts...
Drawdown Indicators
| ABCL | NTLA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.84% | -96.45% | -0.39% |
Max Drawdown (1Y)Largest decline over 1 year | -54.94% | -71.27% | +16.33% |
Max Drawdown (3Y)Largest decline over 3 years | -75.72% | -86.28% | +10.56% |
Max Drawdown (5Y)Largest decline over 5 years | -91.23% | -96.45% | +5.22% |
Max Drawdown (10Y)Largest decline over 10 years | — | -96.45% | — |
Current DrawdownCurrent decline from peak | -90.77% | -91.37% | +0.60% |
Average DrawdownAverage peak-to-trough decline | -84.16% | -57.19% | -26.97% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 30.23% | 46.34% | -16.11% |
Volatility
ABCL vs. NTLA - Volatility Comparison
The current volatility for AbCellera Biologics Inc. (ABCL) is 24.71%, while Intellia Therapeutics, Inc. (NTLA) has a volatility of 29.47%. This indicates that ABCL experiences smaller price fluctuations and is considered to be less risky than NTLA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ABCL | NTLA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 24.71% | 29.47% | -4.76% |
Volatility (6M)Calculated over the trailing 6-month period | 55.13% | 58.34% | -3.21% |
Volatility (1Y)Calculated over the trailing 1-year period | 77.80% | 98.89% | -21.09% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 66.88% | 81.41% | -14.53% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 70.24% | 78.80% | -8.56% |
Dividends
ABCL vs. NTLA - Dividend Comparison
Neither ABCL nor NTLA has paid dividends to shareholders.
Financials
ABCL vs. NTLA - Financials Comparison
This section allows you to compare key financial metrics between AbCellera Biologics Inc. and Intellia Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ABCL and NTLA have a correlation of 0.54, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NTLA has higher volatility (29.47%) compared to ABCL (24.71%). In terms of maximum drawdown, ABCL dropped -96.84% vs NTLA's -96.45%.
ABCL currently has the higher Sharpe Ratio (0.89 vs 0.66), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ABCL and NTLA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer